TMCnet News
KineMed President and Scientific Founder Marc Hellerstein to Lead Medical Diagnostic and Biomarker Flux Analysis Workshop at the 2014 Metabolic Origins of Disease Scientific SymposiumEMERYVILLE, Calif. --(Business Wire)-- KineMed, Inc. (www.kinemed.com) announced today Marc Hellerstein, M.D., Ph.D., President, CSO, and Scientific Founder of KineMed, will lead the workshop titled "Flux Analysis" and give a presentation titled "Flux through target pathways and molecular networks as biomarkers for medical diagnostics and drug development." Dr. Hellerstein's presentation will take place today March 5th from 8:00-9:30 AM EST, at the Sanford Burnham Metabolic Origins of Disease Symposium taking place in Orlando, Florida. About KineMed, Inc. KineMed is a commercial-stage company focused on applying its propritary biomarker platform technology to drug development with BioPharma partners, prescription and non-prescription medical diagnostics and the pairing of its own drugs with its diagnostic biomarker tests. KineMed's diagnostic biomarker tests directly measure the rate of activity of critical biological pathways that cause or modify disease. This is done by measuring through a single sample the flux, or rate of production and destruction over a period of time, of the key molecules involved in these disease-modifying biological processes, using proprietary mass spectrometric-based methods. KineMed believes that measuring molecular flux rates can provide interpretable information that is predictive for clinically meaningful endpoints for an individual patient and that predictive, personalized data about a patient that can guide healthcare decisions. As a result, KineMed believes that its biomarkers can be used to make drug development more efficient and to guide healthcare decisions by physicians and wellness decisions by consumers. Building on a legacy of collaborative relationships and experience in human disease research in drug development settings, KineMed is currently focused on commercializing biomarker tests and advancing drug leads in six areas: muscle biology, fibrotic diseases, cancer, neurodegenerative diseases, cardiometabolic diseases and skin care. For more information about KineMed, please visit: www.kinemed.com
|
